1-[6-(2,4-dichloro-phenyl)-1,2,3,4-tetrahydro-naphthalen-2-yl]-2-methyl-pyrrolidine | 950593-81-4

• 分子结构分类: 有机化合物 - 木脂素、新木脂素和相关化合物
• 英文名称: 1-[6-(2,4-dichloro-phenyl)-1,2,3,4-tetrahydro-naphthalen-2-yl]-2-methyl-pyrrolidine
• 英文别名: 1-[6-(2,4-Dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-2-yl]-2-methylpyrrolidine
• CAS: 950593-81-4
• 化学式: C₂₁H₂₃Cl₂N
• 分子量: 360.326
• InChiKey: SWRHURLDJJCZJX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.5
• 重原子数：
  24
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR
  申请人：McHardy Stanton Furst

  公开号：US20090163482A1

  公开（公告）日：2009-06-25

  This invention is directed to a compound of formula (I), as defined herein, or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing a compound of formula (I) a process of en preparation of a compound of formula (I), a method of treatment of a disorder or condition that may be treated by antagonizing histamine H3 receptors, the method comprising administering to a mammal in need of such treatment a compound of formula (I) as described above, and a method of treatment of a disorder or condition selected from the group consisting of depression, mood disorders, schizophrenia, anxiety disorders, Alzheimer's disease, attention-deficit hyperactivity disorder (ADHD), psychotic disorders, cognitive disorders, sleep disorders, obesity, dizziness, epilepsy, motion sickness, respiratory diseases, allergy, allergy-induced airway responses, allergic rhinitis, nasal congestion, allergic congestion, congestion, hypotension, cardiovascular disease, diseases of the GI tract, hyper and hypo motility and acidic secretion of the gastro-intestinal tract, the method comprising administering to a mammal in need of such treatment a compound of formula (I) as described above.

  本发明涉及公式（I）的化合物，如本文所定义，或其药学上可接受的盐，含有公式（I）化合物的制药组合物，制备公式（I）化合物的方法，一种通过拮抗组胺H3受体治疗可能被治疗的疾病或症状的方法，该方法包括向需要此类治疗的哺乳动物注射上述的公式（I）化合物，以及一种治疗从以下组中选择的疾病或症状的方法：抑郁症，情绪障碍，精神分裂症，焦虑症，阿尔茨海默病，注意力缺陷多动症（ADHD），精神疾病，认知障碍，睡眠障碍，肥胖症，眩晕，癫痫，晕动病，呼吸系统疾病，过敏，过敏引起的气道反应，过敏性鼻炎，鼻塞，过敏性充血，充血，低血压，心血管疾病，消化道疾病，胃肠道高低运动性和酸性分泌，该方法包括向需要此类治疗的哺乳动物注射上述的公式（I）化合物。